
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Featuring an interview with Dr Lindsey Roeker, including the following topics:
- Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
- Safety of BTK inhibitors in older and frail patients with CLL (3:41)
- Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
- Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
- Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
- Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
- Sequencing, tolerability and future development involving pirtobrutinib (25:57)
- Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
- Clinical considerations in the management of Richter’s transformation (38:14)
- Survival outcomes and quality of life for patients with CLL (41:02)
- Ongoing and future efforts to improve CLL treatment outcomes (45:01)
CME information and select publications
What listeners say about Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.